Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Cancer Epidemiology and Prevention

This article is part of the Research TopicUnraveling Renal Cell Carcinoma: Pathogenesis, Therapeutic Strategies, and Future PerspectivesView all 9 articles

Combined Assessment of ERO1A Expression and CD163+ Tumor-Associated Macrophage Infiltration is Superior to Traditional Assessment Methods in Predicting Clear Cell Renal Cell Carcinoma Prognosis

Provisionally accepted
Tianyu  HongTianyu Hong1Changjie  RenChangjie Ren1Hao  XiangHao Xiang2Yongwei  YuYongwei Yu3Mierxiati  AbudurexitiMierxiati Abudurexiti4Zhong  WangZhong Wang4*Chao  WangChao Wang1*
  • 1Shanghai Pudong New Area Public Interest Hospital, Pudong, China
  • 2Zunyi Medical University, Zunyi, China
  • 3Changhai Hospital Changhai Clinical Research Center, Shanghai, China
  • 4Shanghai Pudong New Area Gongli Hospital, Shanghai, China

The final, formatted version of the article will be published soon.

Purpose: The interplay between cancer cells and tumor-infiltrating immune cells (TIICs) facilitates the development of clear cell renal cell carcinoma (ccRCC). However, it remains unclear whether the combined assessment of tumor biomarkers and TIIC density increases the accuracy of ccRCC prognosis prediction. Methods: ERO1A expression was detected in ccRCC tissue samples and cell lines. ccRCC patients from two hospitals were recruited to investigate the value of ERO1A and other TIIC biomarkers in determining ccRCC prognosis via immunohistochemistry (IHC) and statistical analyses. Results: Compared with that in the corresponding controls, ERO1A expression in ccRCC cell lines and tissues was increased and closely correlated with ccRCC progression. ERO1A expression was positively correlated with the density of infiltrating CD163+ tumor-associated macrophages (TAMs) in ccRCC. Among all groups of patients, ccRCC patients with high expression of both ERO1A and CD163 presented the highest TNM stage or Mayo Clinic stage, size, grade, and necrosis (SSIGN) score, as well as the shortest survival period. Moreover, the independent risk factors for the survival of ccRCC patients included ERO1A expression, CD163+ TAM density, TNM stage, and the SSIGN score. Time-dependent C-index analysis revealed that the combination of ERO1A expression and CD163+ TAM density was superior to either factor alone in predicting ccRCC patient survival. Furthermore, the combination of ERO1A expression and CD163+ TAM density with TNM stage or the SSIGN score had the greatest ability to predict the survival of ccRCC patients. Conclusions: Combining ERO1A expression, CD163+ TAM density, and TNM stage or SSIGN score increases the accuracy of postoperative survival prediction for ccRCC patients.

Keywords: CD163, Clear cell renal cell carcinoma, ERO1A, prognosis, Tumor-associated macrophages

Received: 25 Oct 2025; Accepted: 30 Jan 2026.

Copyright: © 2026 Hong, Ren, Xiang, Yu, Abudurexiti, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Zhong Wang
Chao Wang

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.